Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Pyxis Oncology (Nasdaq: PYXS) reported its Q1 2022 financial results on May 13, 2022, ending the quarter with approximately $247 million in cash. The company anticipates filing INDs for several drug candidates in H2 2022 and H2 2023. R&D expenses decreased to $20.1 million from $32.8 million in Q1 2021, while G&A expenses rose to $11.3 million due to increased personnel costs. The net loss was $31.4 million or $0.97 per share, an improvement compared to the $36.8 million loss in the same period last year.
Pyxis Oncology (Nasdaq: PYXS) will have its President and CEO, Lara Sullivan, participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:40 p.m. PT in Las Vegas, Nevada. The event will be available via webcast on the Investors section of the Pyxis Oncology website. A replay will be archived for 90 days. Pyxis Oncology is dedicated to developing next-generation therapeutics targeting challenging cancers, with a focus on antibody drug conjugates and monoclonal antibodies to enhance treatment efficacy.
Pyxis Oncology has announced a leadership change with Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer, effective April 12, 2022. Jan Pinkas, Ph.D., previously Senior VP of Preclinical Research, has been promoted to this role. The transition comes as the company prepares for IND filings for Anti-EDB (PYX-201) and Anti-Siglec-15 (PYX-106) in the second half of 2022, signaling a commitment to advancing its clinical programs and therapeutics aimed at treating difficult cancers.
Pyxis Oncology announced promising preclinical data for PYX-106, an anti-Siglec-15 monoclonal antibody, presented at the 2022 AACR Annual Meeting. The findings suggest that PYX-106 effectively inhibits tumor growth in a mouse model while demonstrating a long half-life in non-human primate studies. This candidate aims to expand treatment options for patients with tumors resistant to current therapies. The IND filing is anticipated in the second half of 2022.
Pyxis Oncology has obtained exclusive rights to develop and commercialize Biosion's anti-Siglec-15 monoclonal antibody, BSI-060T, now known as PYX-106. The deal includes a $10 million upfront fee for Biosion, with potential milestone payments totaling $222.5 million and royalties on future sales. Pyxis plans to submit an IND to the FDA by late 2022 and initiate a Phase 1 trial. The new addition is expected to address significant medical needs in solid tumors, primarily non-small cell lung cancer and head and neck cancer.
Pyxis Oncology (PYXS) has expanded its immuno-oncology pipeline with the in-licensing of anti-Siglec-15 (now PYX-106) from Biosion and the introduction of its first internally developed candidate, anti-KLRG1 (PYX-102). The company reported cash reserves of approximately $253 million, expected to fund operations through Q3 2024, and aims to file INDs for various candidates in the upcoming years. R&D expenses rose to $51.1 million in 2021, reflecting investments in multiple antibody-drug conjugates. The net loss was $76 million, primarily due to these developments.
Pyxis Oncology (Nasdaq: PYXS) announced a conference call and live webcast on March 29, 2022, at 8:00 a.m. ET to discuss corporate updates. Interested parties can join via teleconference at (833) 945-2461 (domestic) or (520) 809-9726 (international) using Conference ID 5458057. The webcast can be accessed through this link or on their Investors section of the website. A replay will be available within two hours of the call and archived for 90 days. Pyxis Oncology focuses on difficult-to-treat cancers.
Axcella Therapeutics (Nasdaq: AXLA) announced the appointment of Robert Crane as its new Chief Financial Officer. Crane brings over 35 years of experience in life sciences, having raised over a billion dollars in capital and contributing significantly to previous companies' successes. Axcella's President, Bill Hinshaw, emphasized Crane's financial expertise and operational mindset at a pivotal moment for the company as it advances its clinical programs. Axcella aims to share crucial clinical data later this year, which may positively impact investor sentiment and facilitate growth opportunities.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be added to the Russell 2000® Index, effective December 20, 2021. This move follows the successful completion of their IPO in October 2021. The company, focused on developing next-generation therapeutics for challenging cancers, aims to leverage this inclusion to connect with a broader investor base. The Russell indexes are crucial for investment managers, with approximately $10.6 trillion in assets benchmarked against them.
Pyxis Oncology appoints Martina Molsbergen as Interim Chief Business Officer to enhance corporate strategy and business development efforts. With over 30 years of experience, Molsbergen will oversee existing partnerships and seek new opportunities. She has a proven record of over 450 successful deals and aims to leverage the company's $300 million raised in 2021 to advance its clinical trials. Under her leadership, Pyxis looks to grow through strategic collaborations and a robust development pipeline targeting challenging cancers.